ResoundingHealth
Search
  
Basic Drug Info
Drug Name:ALPHAGAN P
Manufacturer:Allergan, Inc.
Other Info:

Elevated IOP presents a major risk factor in glaucomatous field loss.

The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.

Brimonidine tartrate has the action of lowering intraocular pressure with minimal effect on cardiovascular and pulmonary parameters.Clinical studies were conducted to evaluate the safety, efficacy, and acceptability of ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.15% compared with ALPHAGAN® administered three-times-daily in patients with open-angle glaucoma or ocular hypertension.

Those results indicated that ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.15% is comparable in IOP lowering effect to ALPHAGAN® (brimonidine tartrate ophthalmic solution) 0.2%, and effectively lowers IOP in patients with open-angle glaucoma or ocular hypertension by approximately 2- 6 mmHg.A clinical study was conducted to evaluate the safety, efficacy, and acceptability of ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% compared with ALPHAGAN® administered three-times-daily in patients with open-angle glaucoma or ocular hypertension.

Those results indicated that ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% is equivalent in IOP lowering effect to ALPHAGAN® (brimonidine tartrate ophthalmic solution) 0.2%, and effectively lowers IOP in patients with open-angle glaucoma or ocular hypertension by approximately 2- 6 mmHg.



Clinical Trials:


Indications and Usage
ALPHAGAN® P is indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Intraocular pressure disorder --

Open Angle Glaucoma -- Glaucoma in which the angle of the anterior chamber is open and the trabecular meshwork does not encroach on the base of the iris.

Ocular Hypertension -- A condition in which the intraocular pressure is elevated above normal and which may lead to glaucoma.

Contraindications

ALPHAGAN® P is contraindicated in patients with hypersensitivity to brimonidine tartrate or any component of this medication.

It is also contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy.
Hypersensitivity -- Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.


This web-site is for informational purposes only and is not intended as a substitute for advice from your doctor. It should not to be used for self-diagnosis or treatment.